GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,385.00GBp
24 Dec 2014
Price Change (% chg)

0.00p (+0.00%)
Prev Close
1,385.00p
Open
1,377.00p
Day's High
1,389.50p
Day's Low
1,362.50p
Volume
2,301,306
Avg. Vol
9,596,192
52-wk High
1,709.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.52
Market Cap (Mil.): £67,362.90
Shares Outstanding (Mil.): 4,863.75
Dividend: 19.00
Yield (%): 5.78

Financials

  GSK.L Industry Sector
P/E (TTM): 16.14 38.19 38.61
EPS (TTM): 0.86 -- --
ROI: 16.65 19.00 18.27
ROE: 75.96 19.75 19.14
Search Stocks

Ebola crisis could last through 2015 as marks year since outbreak: expert

LONDON (Thomson Reuters Foundation) - The Ebola crisis in West Africa that claimed its first victim exactly a year ago is likely to last until the end of 2015, according to a scientist who helped to discover the virus.

24 Dec 2014

Ebola crisis could last through 2015 as marks year since outbreak-expert-TRFN

LONDON, Dec 24 (Thomson Reuters Foundation) - The Ebola crisis in West Africa that claimed its first victim exactly a year ago is likely to last until the end of 2015, according to a scientist who helped to discover the virus.

24 Dec 2014

NewLink, GSK get U.S. funding for faster development of Ebola vaccines

- The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.

23 Dec 2014

NewLink, GSK get U.S. funding for faster development of Ebola vaccines

Dec 23 - The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines.

23 Dec 2014

Exclusive: Can the blood of Ebola survivors create a cure?

CHICAGO - For months, Vanderbilt University researcher Dr. James Crowe has been desperately seeking access to the blood of U.S. Ebola survivors, hoping to extract the proteins that helped them overcome the deadly virus for use in new, potent drugs. | Video

22 Dec 2014

GSK Ebola vaccine trial seen moving to wider phase in February

GENEVA - Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

19 Dec 2014

GSK Ebola vaccine trial seen moving to wider phase in February

GENEVA, Dec 19 - Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

19 Dec 2014

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

18 Dec 2014

GSK shareholders approve asset swap deal with Novartis

LONDON, Dec 18 - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.

18 Dec 2014

GlaxoSmithKline shingles vaccine hits goal in major study

LONDON, Dec 18 - An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business.

18 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks